Breaking Finance News

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has been downgraded to Neutral in a statement by JPMorgan Chase & Co. earlier today.

Having a price of $6.02, Merrimack Pharmaceuticals Inc (NASDAQ:MACK) traded -1.42% lower on the day. With the last close down -5.18% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. MACK has recorded a 50-day average of $5.19 and a two hundred day average of $6.22. Trade Volume was down over the average, with 541,655 shares of MACK changing hands under the typical 2,555,460

JPMorgan Chase & Co. has downgraded Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to Neutral in a statement released on 10/7/2016.

Recent Performance Chart

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Merrimack Pharmaceuticals Inc has with a one year low of $4.39 and a one year high of $10.85 and has a market capitalization of $0.

General Information About Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.